Nuveen
KURA icon

Nuveen’s Kura Oncology KURA Stock Holding History

Nuveen’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.83M Buy
166,670
+14,807
+10% +$140K ﹤0.01% 2615
2026
Q1 		$1.23M Buy
151,863
+793
+0.5% +$6.81K ﹤0.01% 2487
2025
Q4 		$1.57M Sell
151,070
-248,719
-62% -$2.61M ﹤0.01% 2399
2025
Q3 		$3.54M Hold
399,789
– – ﹤0.01% 2073
2025
Q2 		$2.31M Buy
399,789
+162,842
+69% +$998K ﹤0.01% 2239
2025
Q1 		$1.56M Buy
236,947
+54,279
+30% +$423K ﹤0.01% 2444
2024
Q4 		$1.59M Sell
182,668
-74,212
-29% -$1.07M ﹤0.01% 2483
2024
Q3 		$5.02M Sell
256,880
-5,171
-2% -$105K ﹤0.01% 1984
2024
Q2 		$5.4M Buy
262,051
+51,885
+25% +$1.07M ﹤0.01% 1910
2024
Q1 		$4.48M Buy
210,166
+10,753
+5% +$209K ﹤0.01% 2043
2023
Q4 		$2.87M Sell
199,413
-531,130
-73% -$5.22M ﹤0.01% 2241
2023
Q3 		$6.66M Buy
730,543
+70,585
+11% +$717K ﹤0.01% 1716
2023
Q2 		$6.98M Sell
659,958
-143
-0% -$1.69K ﹤0.01% 1728
2023
Q1 		$8.07M Sell
660,101
-35,560
-5% -$444K ﹤0.01% 1620
2022
Q4 		$8.63M Buy
695,661
+355,277
+104% +$5.16M ﹤0.01% 1590
2022
Q3 		$4.65M Buy
340,384
+114,042
+50% +$1.76M ﹤0.01% 1949
2022
Q2 		$4.15M Sell
226,342
-298,844
-57% -$4.3M ﹤0.01% 2066
2022
Q1 		$8.35M Buy
525,186
+75,340
+17% +$1.09M ﹤0.01% 1765
2021
Q4 		$6.3M Sell
449,846
-19,746
-4% -$320K ﹤0.01% 1978
2021
Q3 		$8.79M Buy
469,592
+95,684
+26% +$1.8M ﹤0.01% 1869
2021
Q2 		$7.8M Buy
373,908
+83,989
+29% +$2.09M ﹤0.01% 2009
2021
Q1 		$8.2M Sell
289,919
-441,950
-60% -$14M ﹤0.01% 1905
2020
Q4 		$23.9M Sell
731,869
-105,583
-13% -$3.71M 0.01% 1137
2020
Q3 		$25.7M Buy
837,452
+49,476
+6% +$1.09M 0.01% 917
2020
Q2 		$12.8M Buy
787,976
+400,579
+103% +$5.78M 0.01% 1314
2020
Q1 		$3.85M Buy
387,397
+79,639
+26% +$912K ﹤0.01% 1859
2019
Q4 		$4.23M Sell
307,758
-75,802
-20% -$1.12M ﹤0.01% 2076
2019
Q3 		$5.82M Buy
383,560
+286,685
+296% +$5.1M ﹤0.01% 1880
2019
Q2 		$1.91M Buy
+96,875
New +$1.61M ﹤0.01% 2456

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Nuveen's KURA Position: Q2 2026 in Review

Nuveen increased its Kura Oncology (KURA) stake by 9.8% in Q2 2026, buying an estimated $140K and bringing the position to 166,670 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #2615.

Nuveen first reported a position in KURA in Q2 2019 and has held it in 29 quarters since. The position peaked at $25.7M in Q3 2020. 221 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • Nuveen held 166,670 shares of Kura Oncology worth $1.83M as of Q2 2026.
  • Nuveen bought 14,807 Kura Oncology shares in Q2 2026, an estimated $140K.
  • Kura Oncology made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2615 holding.
  • Nuveen first reported a position in Kura Oncology in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Kura Oncology position peaked at $25.7M in Q3 2020.
  • 221 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.